keyword
MENU ▼
Read by QxMD icon Read
search

smouldering myeloma

keyword
https://www.readbyqxmd.com/read/28903571/asymptomatic-and-treatment-requiring-multiple-myeloma-data-from-the-czech-registry-of-monoclonal-gammopathies
#1
L Brozova, J Jarkovský, L Pour, J Minárik, A Jungová, E Gregora, I Spicka, V Maisnar, R Hájek
BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) and smouldering multiple myeloma (SMM) are premalignant stages of multiple myeloma (MM). MM is a malignancy of plasma cells, which is associated with a median overall survival of 5 to 7 years. MM accounts for approximately 10% of hematological malignancies. PATIENTS AND METHODS: Descriptive analysis of data from 19 Czech centres collected in the Registry of Monoclonal Gammopathies (RMG) was performed...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/28835722/evolutionary-biology-of-high-risk-multiple-myeloma
#2
REVIEW
Charlotte Pawlyn, Gareth J Morgan
The outcomes for the majority of patients with myeloma have improved over recent decades, driven by treatment advances. However, there is a subset of patients considered to have high-risk disease who have not benefited. Understanding how high-risk disease evolves from more therapeutically tractable stages is crucial if we are to improve outcomes. This can be accomplished by identifying the genetic mechanisms and mutations driving the transition of a normal plasma cell to one with the features of the following disease stages: monoclonal gammopathy of undetermined significance, smouldering myeloma, myeloma and plasma cell leukaemia...
August 24, 2017: Nature Reviews. Cancer
https://www.readbyqxmd.com/read/28726797/multiple-myeloma
#3
REVIEW
Shaji K Kumar, Vincent Rajkumar, Robert A Kyle, Mark van Duin, Pieter Sonneveld, María-Victoria Mateos, Francesca Gay, Kenneth C Anderson
Multiple myeloma is a malignancy of terminally differentiated plasma cells, and patients typically present with bone marrow infiltration of clonal plasma cells and monoclonal protein in the serum and/or urine. The diagnosis of multiple myeloma is made when clear end-organ damage attributable to the plasma cell proliferative disorder or when findings that suggest a high likelihood of their development are present. Distinguishing symptomatic multiple myeloma that requires treatment from the precursor stages of monoclonal gammopathy of undetermined significance and smouldering multiple myeloma is important, as observation is the standard for those conditions...
July 20, 2017: Nature Reviews. Disease Primers
https://www.readbyqxmd.com/read/28429426/age-related-health-care-disparities-in-multiple-myeloma
#4
Mathieu Puyade, Gautier Defossez, François Guilhot, Xavier Leleu, Pierre Ingrand
Age is a well-known factor in solid tumours linked to lower adherence to guidelines. Scarce data exist for haematologic malignancies such as multiple myeloma (MM). The aim of the study was to investigate the relationships among age, adherence to guidelines in MM, and overall survival (OS).The Poitou-Charentes cancer registry has exhaustively registered incident cases of MM from 2008 to 2010. Diagnosis, staging, prognosis, and first-line treatment were compared to the international guidelines. Three hundred and sixty-seven patients aged 36 to 93 years were included...
April 21, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28371346/dramatic-resolution-of-disseminated-pyoderma-gangrenosum-associated-with-monoclonal-gammopathy-after-therapy-with-bortezomib-and-dexamethasone
#5
Virginia Velasco-Tamariz, Gonzalo Carreño-Tarragona, Fátima Tous-Romero, Elena Gil-de la Cruz, Estela Martín-Clavero, Raquel Rivera-Díaz
Pyoderma gangrenosum (PG) is an uncommon inflammatory and ulcerative skin disorder, which is commonly associated with systemic conditions such as inflammatory bowel disease, arthritis and haematological malignancies. It is widely stated that control of the underlying diseases may lead to resolution of PG. However, standard of care dictates that patients suffering with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (MM) should not receive therapy unless they progress to symptomatic MM...
March 29, 2017: International Wound Journal
https://www.readbyqxmd.com/read/28368259/role-of-18-f-fdg-pet-ct-in-the-diagnosis-and-management-of-multiple-myeloma-and-other-plasma-cell-disorders-a-consensus-statement-by-the-international-myeloma-working-group
#6
REVIEW
Michele Cavo, Evangelos Terpos, Cristina Nanni, Philippe Moreau, Suzanne Lentzsch, Sonja Zweegman, Jens Hillengass, Monika Engelhardt, Saad Z Usmani, David H Vesole, Jesus San-Miguel, Shaji K Kumar, Paul G Richardson, Joseph R Mikhael, Fernando Leal da Costa, Meletios-Athanassios Dimopoulos, Chiara Zingaretti, Niels Abildgaard, Hartmut Goldschmidt, Robert Z Orlowski, Wee Joo Chng, Hermann Einsele, Sagar Lonial, Bart Barlogie, Kenneth C Anderson, S Vincent Rajkumar, Brian G M Durie, Elena Zamagni
The International Myeloma Working Group consensus aimed to provide recommendations for the optimal use of (18)fluorodeoxyglucose ((18)F-FDG) PET/CT in patients with multiple myeloma and other plasma cell disorders, including smouldering multiple myeloma and solitary plasmacytoma. (18)F-FDG PET/CT can be considered a valuable tool for the work-up of patients with both newly diagnosed and relapsed or refractory multiple myeloma because it assesses bone damage with relatively high sensitivity and specificity, and detects extramedullary sites of proliferating clonal plasma cells while providing important prognostic information...
April 2017: Lancet Oncology
https://www.readbyqxmd.com/read/27696255/vision-statement-for-multiple-myeloma-future-directions
#7
Kenneth C Anderson
There has been great progress in the management and patient outcome in multiple myeloma due to the use of novel agents including immunomodulatory drugs and proteasome inhibitors; nonetheless, novel agents remain an urgent need. The three promising Achilles heals or vulnerabilities to be targetted in novel therapies include: protein degradation by the ubiquitin proteasome or aggresome pathways; restoring autologous antimyeloma immunity; and targeting aberrant biology resulting from constitutive and ongoing DNA damage in tumour cells...
2016: Cancer Treatment and Research
https://www.readbyqxmd.com/read/27609508/the-singapore-myeloma-study-group-consensus-guidelines-for-the-management-of-patients-with-multiple-myeloma
#8
Sanjay de Mel, Yunxin Chen, Sathish Kumar Gopalakrishnan, Melissa Ooi, Constance Teo, Daryl Tan, Min Li Claire Teo, Allison Cy Tso, Lian King Lee, Chandramouli Nagarajan, Yeow Tee Goh, Wee Joo Chng
Multiple myeloma (MM) is an incurable plasma cell neoplasm with an incidence of 100 patients per year in Singapore. Major advances have been made in the diagnosis, risk stratification and treatment of MM in the recent past. The reclassification of a subset of patients with smouldering MM, based on high-risk biomarkers, and the development of the revised international staging system are among the key new developments in diagnosis and staging. The use of novel agent-based treatment has resulted in significant improvements in the survival and quality of life of many patients with MM...
February 2017: Singapore Medical Journal
https://www.readbyqxmd.com/read/27531699/genomic-complexity-of-multiple-myeloma-and-its-clinical-implications
#9
REVIEW
Salomon Manier, Karma Z Salem, Jihye Park, Dan A Landau, Gad Getz, Irene M Ghobrial
Multiple myeloma (MM) is a genetically complex disease that evolves from pre-malignant stages, such as monoclonal gammaopathy of undetermined significance and smouldering multiple myeloma, and progresses to symptomatic MM; this continuum provides a unique framework to study the sequential genomic evolution of MM. In the past 5 years, results from large-scale whole-exome sequencing studies have provided new insights into the clonal heterogeneity and evolution of the disease. Moreover, the recurrent co-occurrence of genomic events helps to dissect the genomic complexity underlying tumour progression...
February 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27463358/cured-multiple-myeloma-followed-by-primary-malignant-lymphoma-of-the-lung
#10
A Schattner, F Nissim, A Berrebi
A 56-year-old patient was found to have smouldering myeloma which remained asymptomatic and untreated for 13 years. Localised osteolytic lesions then appeared, which responded to local irradiation. Six years later, an increased serum M-protein became evident (IgG$LD, 3 gr/dl) associated with 35% plasma cells in the bone marrow, which necessitated melphalan/prednisone therapy. A prolonged complete remission was achieved lasting 6 years. Thereafter, the patient developed a myelodysplastic syndrome with leukopenia and refractory anemia and he finally died of pulmonary disease...
1991: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27402145/lenalidomide-plus-dexamethasone-versus-observation-in-patients-with-high-risk-smouldering-multiple-myeloma-quiredex-long-term-follow-up-of-a-randomised-controlled-phase-3-trial
#11
RANDOMIZED CONTROLLED TRIAL
María-Victoria Mateos, Miguel-Teodoro Hernández, Pilar Giraldo, Javier de la Rubia, Felipe de Arriba, Lucía López Corral, Laura Rosiñol, Bruno Paiva, Luis Palomera, Joan Bargay, Albert Oriol, Felipe Prosper, Javier López, José-María Arguiñano, Nuria Quintana, José-Luis García, Joan Bladé, Juan-José Lahuerta, Jesús-F San Miguel
BACKGROUND: The standard of care for smouldering multiple myeloma is observation. We did the QuiRedex study to compare early treatment with lenalidomide plus dexamethasone with observation in patients with high-risk smouldering multiple myeloma. Here we report the long-term follow-up results of the trial. METHODS: We did this open-label, randomised, controlled phase 3 study at 19 centres in Spain and three centres in Portugal. Patients aged 18 years or older with high-risk smouldering multiple myeloma were randomly assigned (1:1), via a computerised random number generator, to receive either early treatment with lenalidomide plus dexamethasone or observation, with dynamic balancing to maintain treatment balance within the two groups...
August 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27402144/early-treatment-for-high-risk-smouldering-myeloma-has-the-time-come
#12
Heinz Ludwig
No abstract text is available yet for this article.
August 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27166317/multiple-myeloma-and-multiple-plasmacytomas-associated-with-free-gamma-heavy-chain-free-kappa-light-chain-and-iggk-paraproteins-an-unusual-triple-gammopathy
#13
William I Deighan, Maurice J O'Kane, Feargal P McNicholl, David F Keren
Multiple myeloma is a malignant plasma cell dyscrasia that is becoming more prevalent in an increasingly ageing population. It is a complex disease with clinical phases ranging from the premalignant monoclonal gammopathy of undetermined significance to asymptomatic (smouldering) myeloma and then symptomatic myeloma; the latter occasionally terminating in the clonal proliferation of plasma cells outside the bone marrow. We present a patient whose clonally evolved disease from monoclonal gammopathy of undetermined significance to multiple myeloma demonstrated the presence of an unusual combination of monoclonal immunoproteins...
November 2016: Annals of Clinical Biochemistry
https://www.readbyqxmd.com/read/27164915/mri-in-multiple-myeloma-a-pictorial-review-of-diagnostic-and-post-treatment-findings
#14
REVIEW
Julie C Dutoit, Koenraad L Verstraete
Magnetic resonance imaging (MRI) is increasingly being used in the diagnostic work-up of patients with multiple myeloma. Since 2014, MRI findings are included in the new diagnostic criteria proposed by the International Myeloma Working Group. Patients with smouldering myeloma presenting with more than one unequivocal focal lesion in the bone marrow on MRI are considered having symptomatic myeloma requiring treatment, regardless of the presence of lytic bone lesions. However, bone marrow evaluation with MRI offers more than only morphological information regarding the detection of focal lesions in patients with MM...
August 2016: Insights Into Imaging
https://www.readbyqxmd.com/read/26999424/monoclonal-gammopathy-associated-pure-red-cell-aplasia
#15
Neha Korde, Yong Zhang, Kelsey Loeliger, Andrea Poon, Olga Simakova, Adriana Zingone, Rene Costello, Richard Childs, Pierre Noel, Samuel Silver, Mary Kwok, Clifton Mo, Neal Young, Ola Landgren, Elaine Sloand, Irina Maric
Pure red cell aplasia (PRCA) is a rare disorder characterized by inhibition of erythroid precursors in the bone marrow and normochromic, normocytic anaemia with reticulocytopenia. Among 51 PRCA patients, we identified 12 (24%) patients having monoclonal gammopathy, monoclonal gammopathy of undetermined significance or smouldering multiple myeloma, with presence of monoclonal protein or abnormal serum free light chains and atypical bone marrow features of clonal plasmacytosis, hypercellularity and fibrosis. Thus far, three patients treated with anti-myeloma based therapeutics have responded with reticulocyte recovery and clinical transfusion independence, suggesting plasma cells play a key role in the pathogenesis of this specific monoclonal gammopathy-associated PRCA...
June 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/26991959/increased-microcirculation-detected-by-dynamic-contrast-enhanced-magnetic-resonance-imaging-is-of-prognostic-significance-in-asymptomatic-myeloma
#16
Jens Hillengass, Judith Ritsch, Maximilian Merz, Barbara Wagner, Christina Kunz, Thomas Hielscher, Hendrik Laue, Tobias Bäuerle, Christian M Zechmann, Anthony D Ho, Heinz-Peter Schlemmer, Hartmut Goldschmidt, Thomas M Moehler, Stefan Delorme
This prospective study aimed to investigate the prognostic significance of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) as a non-invasive imaging technique delivering the quantitative parameters amplitude A (reflecting blood volume) and exchange rate constant kep (reflecting vascular permeability) in patients with asymptomatic monoclonal plasma cell diseases. We analysed DCE-MRI parameters in 33 healthy controls and 148 patients with monoclonal gammopathy of undetermined significance (MGUS) or smouldering multiple myeloma (SMM) according to the 2003 IMWG guidelines...
July 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/26614625/multiple-myeloma-and-physical-activity-a-scoping-review
#17
REVIEW
Lee Smith, Orla McCourt, Malgorzata Henrich, Bruce Paton, Kwee Yong, Jane Wardle, Abigail Fisher
OBJECTIVES: Multiple myeloma is the second most common haematological cancer. A growing body of literature is emerging that investigates the role physical activity plays in all stages of multiple myeloma (prevention and survivorship) and to date no attempt has been made to collate and understand this literature. Therefore, this scoping review aims to (1) outline what is already known about physical activity in all stages of multiple myeloma (2) map the literature on physical activity and multiple myeloma and (3) identify future directions for research...
November 27, 2015: BMJ Open
https://www.readbyqxmd.com/read/26259316/tc-99m-sestamibi-scanning-in-multiple-myeloma-a-new-look-with-spect-ct
#18
Karuna Luthra, Abhay Bhave, R D Lele
UNLABELLED: A variety of diagnostic tools including biochemistry, radiological imaging bone marrow studies and recently metabolic imaging with FDG PET are used for assessment of disease extent in myeloma. AIM: To evaluate the role of metabolic imaging with Tc99m Sestamibi (Mibi) SPECT-CT in Multiple myeloma. MATERIALS AND METHODS: Patients in various stages of Myeloma were scanned after 20mCi Tc99m Sestamibi was injected i/v. Whole body planar scans were obtained with a dual head gamma camera and SPECT-CT imaging was done...
September 2014: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/26221971/time-to-redefine-myeloma
#19
EDITORIAL
Guy Pratt, Stella Bowcock, Andrew Chantry, Gordon Cook, Graham Jackson, Maggie Lai, Eric Low, Nicola Mulholland, Roger Owen, Neil Rabin, Karthik Ramasamy, John A Snowden, Matthew Streetly, Ashutosh Wechalekar, Kwee Yong, Jenny Bird
In November 2014 the International Myeloma Working Group (IMWG) revised the definition of multiple myeloma, such that asymptomatic patients with newly diagnosed multiple myeloma without any of the traditional 'CRAB' (hypercalcaemia, renal impairment, anaemia, bone disease) end organ damage criteria but with one of three new criteria would be recommended to start treatment. Previously, the standard of care for such patients was expectant management. These three new criteria are: greater than 60% clonal plasma cells on bone marrow biopsy, a serum free light chain (sFLC) ratio of >100 (the involved sFLC must be >100 mg/l) and greater than one unequivocal focal lesion on advanced imaging (low dose whole body computerized tomography, magnetic resonance imaging, (18) F fluorodeoxyglucose positron emission tomography)...
October 2015: British Journal of Haematology
https://www.readbyqxmd.com/read/25870934/screening-whole-spine-magnetic-resonance-imaging-in-multiple-myeloma
#20
J Wight, A Stillwell, E Morris, B Grant, H C Lai, I Irving
BACKGROUND: Magnetic resonance imaging (MRI) is the most sensitive method for detecting focal spinal disease (FSD) in multiple myeloma (MM). It is unclear whether whole spine MRI (WS-MRI) should be employed as a screening test at diagnosis of MM. AIM: To determine the utility of screening WS-MRI at diagnosis of MM. METHODS: A retrospective analysis of data from January 2008 to January 2013 at the Townsville Hospital was performed. At this centre, WS-MRI is used routinely in all newly diagnosed MM...
July 2015: Internal Medicine Journal
keyword
keyword
119004
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"